Ascentage Pharma Group International ADR Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $134.3M0.0% YoYTTM through 31 Dec 2024
Net Income -$55.5MTTM through 31 Dec 2024
Free Cash Flow -$18.6MTTM through 31 Dec 2024
Margins
| Current | |
|---|---|
| Gross Margin | 91.5% |
| Operating Margin | -891.5% |
| Net Margin | -41.3% |
Returns
-147.9%ROE
Balance Sheet Health
Debt / Equity3.24x
Current Ratio1.26x
Net Debt-$502Knet cash position
Cash & Equivalents$122.4M
Quality Metrics
FCF Margin-13.8%
Multi-Year Trend
RevenueFY2024: $980.7M
Diluted EPSFY2024: $-1.34
Dividend
No dividend
Capital Allocation
Capex Intensity2.5%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Olverembatinib (China Product Sales) | $62.2M | +81.0% | View detailsPoised for continued growth in China driven by full-year National Reimbursement Drug List (NRDL) coverage across all approved indications. |
| Lisaftoclax (China Product Sales) | $10.1M | View detailsActively pursuing inclusion in China's National Reimbursement Drug List (NRDL) to enhance affordability and market adoption. |
Financials converted at 7.2981 from RMB.
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.